Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Pharma Industry Braces For Environmental Protection Regulations

This article was originally published in PharmAsia News

Executive Summary

The State Environmental Protection Administration of China published an online draft on the discharge standard of pollutants for the pharmaceutical industry last October to solicit feedback. This, and a catalog on high-pollution and high-risk products, are expected to be rolled out next year. Analysts observe that an enterprise will face more difficulty implementing the new environmental standards than getting a national good manufacturing practises authentication as additional measures greatly increase production costs. Local environmental protection expenses are as high as 350 million yuan for Shijiazhuang Pharmaceutical Group Co. Ltd. The new regulations will put pressure on the pharmaceutical industry, and the government is looking at green tax policies to provide incentives for environmental investment. (Click here for more)

You may also be interested in...



UK MHRA To Medtech: Check Before Applying For Non-COVID-19 Trials

The UK regulator is expecting a rise in amendments and deviations to ongoing clinical investigations of medical devices due to the COVID-19 pandemic and has issued advice on how companies should manage these. 

Mylan Bids To Win EU Approval For Upjohn Merger

Mylan and Pfizer’s Upjohn, already facing a delay to their proposed merger, may have to overcome regulatory barriers to get the deal over the line.

IGBA Criticizes Export Restrictions

National export restrictions on medicines have been slammed by the international off-patent pharmaceutical industry as being “counter-productive” during the coronavirus crisis. The IGBA is instead urging international co-operation and transparency, pointing to a positive example of supply-chain connectivity in the Asia-Pacific region.

UsernamePublicRestriction

Register

SC065939

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel